10 July 2013

Otsuka Establishes European R&D Headquarters in the UK

Tokyo & Uxbridge, United Kingdom – 10 July 2013 - Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced the formation of Otsuka Europe Development and Commercialisation Ltd. (OEDC).

Established on July 1st, 2013, OEDC is an important milestone for Otsuka's growing European pharmaceutical business and a significant long-term investment for Otsuka in Europe. OEDC will be Otsuka's European Research and Development Headquarters, working alongside Otsuka Pharmaceutical Europe Ltd (OPEL) to ensure the successful development and commercialisation of our products. OEDC and OPEL are separate entities based in the same location, just outside London.

"We are delighted to establish this new company in the UK," said Dean Haubrich, President and CEO of OEDC. "We believe that Otsuka has a great deal to contribute to the health and well-being of people in Europe and we look forward to reinforcing our strong, positive presence."

"The opening of OEDC is a very important milestone for Otsuka in Europe," said Ole Vahlgren, President and CEO of OPEL "This significant long-term investment will strengthen Otsuka Europe's continued efforts to bring Otsuka's innovative medicines to patients across Europe."

Otsuka Pharmaceutical Co., Ltd. is a global healthcare company. Otsuka is a wholly owned subsidiary of Otsuka Holdings Co., Ltd., the holding company for the Otsuka Group. The Otsuka Group has business operations in 25 countries and regions around the world, with consolidated sales of approximately US$13 billion or €10 billion for fiscal year 2012. 

Source: Otsuka Pharmaceutical